【ChiCTR2600121913】To evaluate and compare the effectiveness of Coenzyme Q10 versus Vitamin E supplementation on serum testosterone levels, luteinizing hormone levels, and semen parameters in men with idiopathic primary infertility.
ChiCTR2600121913
结束
/
/
/
2026-04-07
/
/
Male infertility
To evaluate and compare the effectiveness of Coenzyme Q10 versus Vitamin E supplementation on serum testosterone levels, luteinizing hormone levels, and semen parameters in men with idiopathic primary infertility.
Effectiveness of Coenzyme Q10 versus Vitamin E in improving serum testosterone, luteinizing hormone levels and semen parameters in men with idiopathic primary infertility: A randomized controlled study
25000
To compare the effectiveness of Coenzyme Q10 and Vitamin E supplementation in improving serum testosterone, luteinizing hormone levels, and semen parameters in men with idiopathic primary infertility.
随机平行对照
其它
Participants were randomized into two groups using a computer-generated randomization sequence prepared by an independent investigator not involved in recruitment or assessment.
Open-label
Institute of Kidney Diseases (IKD), Hayatabad Medical Complex
/
50
/
2023-02-01
2024-06-30
/
1. Male patients aged 20–40 years; 2. History of primary infertility for more than one year despite regular unprotected intercourse; 3. Diagnosis of idiopathic infertility after clinical evaluation; 4. Normal semen parameters according to WHO manual 6th edition; 5. Willingness to participate and provide written informed consent.；
请登录查看1. Known endocrine or systemic disease; 2. History of cryptorchidism, varicocele, testicular hypotrophy, or genital tract infection; 3. Obstructive azoospermia or presence of antisperm antibodies; 4. Previous use of hormonal therapy or antioxidant supplements; 5. Female factor infertility in the partner.；
请登录查看Department of Urology, Institute of Kidney Diseases (IKD), Hayatabad Medical Complex
25000
Department of Urology, Institute of Kidney Diseases (IKD), Hayatabad Medical Complex的其他临床试验
Institute of Kidney Diseases, Hayatabad Medical Complex, Phase 4, Peshawar, Khyber Pakhtunkhwa, Pakistan的其他临床试验
最新临床资讯
-
Nat Rev Clin Oncol｜AI赋能肿瘤临床试验：从流程优化到证据生成的全景透视
智药邦2026-08-12
-
康臣药业1类新药糖肾方“芪箭颗粒”获NMPA临床研究许可
康臣药业2026-08-12
-
璎黎药业2026-08-12
-
幂方健康基金2026-08-12
-
细胞与基因治疗领域2026-08-12
-
云南白药2026-08-12
-
细胞治疗前沿2026-08-12
-
广州达博生物制品有限公司2026-08-12
-
医药笔记2026-08-12
-
医药笔记2026-08-12
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29